South African drugmaker Aspen Pharmacare has announced its target to secure regulatory approval for the medication Mounjaro (tirzepatide) in sub-Saharan African markets before the year ends. This move represents a strategic effort to address the growing burden of diabetes and obesity in the region, conditions that have seen an alarming rise in recent decades. Mounjaro, a dual GLP-1 and GIP receptor agonist originally developed by Eli Lilly, has demonstrated significant efficacy in glycemic control and weight loss in global clinical trials.
The context is critical: The International Diabetes Federation estimates that over 24 million adults in Africa were living with diabetes in 2021, a figure projected to increase by 129% by 2045. Access to innovative medicines for non-communicable diseases on the continent is often hampered by challenges of affordability, supply chain infrastructure, and regulatory capacity. Aspen, with its extensive manufacturing and distribution network across the continent, aims to leverage its local expertise to navigate these hurdles. The company has been strengthening its portfolio beyond generics and antiretrovirals, seeking partnerships for specialized therapies.
"Our mission is to enhance access to essential and cutting-edge medicines for African patients," stated a senior Aspen spokesperson. "The pursuit of Mounjaro approval underscores our commitment to addressing the dual epidemic of diabetes and obesity, which are significant risk factors for cardiovascular disease and other complications." The process will involve submissions to key regulatory authorities in countries such as South Africa, Kenya, Nigeria, and Ghana, leveraging regional collaborative review pathways where possible.
The potential impact of a successful introduction is considerable. It could offer a new effective treatment option for millions of patients, alleviate some of the burden on public health systems, and position Aspen as a leader in the metabolic care space in Africa. However, experts note that pricing and supply agreements will be determining factors for real-world access. The conclusion is clear: Aspen's race for Mounjaro approval marks a significant step toward reducing the health equity gap for innovative therapies in Africa, though its ultimate success will depend on implementation that prioritizes sustainability and broad access.